117 related articles for article (PubMed ID: 21062644)
41. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.
Yamamoto A; Lucas JJ; Hen R
Cell; 2000 Mar; 101(1):57-66. PubMed ID: 10778856
[TBL] [Abstract][Full Text] [Related]
42. Lack of minocycline efficiency in genetic models of Huntington's disease.
Mievis S; Levivier M; Communi D; Vassart G; Brotchi J; Ledent C; Blum D
Neuromolecular Med; 2007; 9(1):47-54. PubMed ID: 17114824
[TBL] [Abstract][Full Text] [Related]
43. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.
Duan W; Peng Q; Masuda N; Ford E; Tryggestad E; Ladenheim B; Zhao M; Cadet JL; Wong J; Ross CA
Neurobiol Dis; 2008 Jun; 30(3):312-322. PubMed ID: 18403212
[TBL] [Abstract][Full Text] [Related]
44. Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington's disease.
Stepanova P; Kumar D; Cavonius K; Korpikoski J; Sirjala J; Lindholm D; Voutilainen MH
Sci Rep; 2023 Feb; 13(1):2953. PubMed ID: 36807563
[TBL] [Abstract][Full Text] [Related]
45. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.
Luthi-Carter R; Strand A; Peters NL; Solano SM; Hollingsworth ZR; Menon AS; Frey AS; Spektor BS; Penney EB; Schilling G; Ross CA; Borchelt DR; Tapscott SJ; Young AB; Cha JH; Olson JM
Hum Mol Genet; 2000 May; 9(9):1259-71. PubMed ID: 10814708
[TBL] [Abstract][Full Text] [Related]
46. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs.
Shen HY; Coelho JE; Ohtsuka N; Canas PM; Day YJ; Huang QY; Rebola N; Yu L; Boison D; Cunha RA; Linden J; Tsien JZ; Chen JF
J Neurosci; 2008 Mar; 28(12):2970-5. PubMed ID: 18354001
[TBL] [Abstract][Full Text] [Related]
47. Axonopathy in Huntington's disease.
Li JY; Conforti L
Exp Neurol; 2013 Aug; 246():62-71. PubMed ID: 22921535
[TBL] [Abstract][Full Text] [Related]
48. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
[TBL] [Abstract][Full Text] [Related]
49. [Huntington chorea in Drosophila and mice: toward new therapeutic steps].
Liévens JC; Birman S
Med Sci (Paris); 2003 May; 19(5):593-9. PubMed ID: 12836393
[TBL] [Abstract][Full Text] [Related]
50. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.
Chiu CT; Liu G; Leeds P; Chuang DM
Neuropsychopharmacology; 2011 Nov; 36(12):2406-21. PubMed ID: 21796107
[TBL] [Abstract][Full Text] [Related]
51. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.
Schilling G; Coonfield ML; Ross CA; Borchelt DR
Neurosci Lett; 2001 Nov; 315(3):149-53. PubMed ID: 11716985
[TBL] [Abstract][Full Text] [Related]
52. Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning.
Singer P; Wei CJ; Chen JF; Boison D; Yee BK
Behav Brain Res; 2013 Apr; 242():54-61. PubMed ID: 23276608
[TBL] [Abstract][Full Text] [Related]
53. High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice.
Molnár MF; Török R; Szalárdy L; Sümegi E; Vécsei L; Klivényi P
Acta Neurobiol Exp (Wars); 2016; 76(3):176-81. PubMed ID: 27685770
[TBL] [Abstract][Full Text] [Related]
54. Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease.
Potenza RL; Tebano MT; Martire A; Domenici MR; Pepponi R; Armida M; Pèzzola A; Minghetti L; Popoli P
Purinergic Signal; 2007 Sep; 3(4):333-8. PubMed ID: 18404446
[TBL] [Abstract][Full Text] [Related]
55. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1.
Taherzadeh-Fard E; Saft C; Wieczorek S; Epplen JT; Arning L
Neurogenetics; 2010 Oct; 11(4):435-9. PubMed ID: 20512606
[TBL] [Abstract][Full Text] [Related]
56. Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease.
Maglione V; Giallonardo P; Cannella M; Martino T; Frati L; Squitieri F
Am J Med Genet B Neuropsychiatr Genet; 2005 Nov; 139B(1):101-5. PubMed ID: 16184606
[TBL] [Abstract][Full Text] [Related]
57. Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy.
St-Cyr S; Child DD; Giaime E; Smith AR; Pascua CJ; Hahm S; Saiah E; Davidson BL
PLoS One; 2022; 17(8):e0273710. PubMed ID: 36037192
[TBL] [Abstract][Full Text] [Related]
58. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders.
Pasinetti GM; Wang J; Marambaud P; Ferruzzi M; Gregor P; Knable LA; Ho L
Exp Neurol; 2011 Nov; 232(1):1-6. PubMed ID: 21907197
[TBL] [Abstract][Full Text] [Related]
59. Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease.
Tebano MT; Martire A; Chiodi V; Ferrante A; Popoli P
ScientificWorldJournal; 2010 Sep; 10():1768-82. PubMed ID: 20842321
[TBL] [Abstract][Full Text] [Related]
60. Nebulization of low-dose aspirin ameliorates Huntington's pathology in N171-82Q transgenic mice.
Mondal S; Prieto S; Rangasamy SB; Dutta D; Pahan K
NeuroImmune Pharm Ther; 2024 Mar; 3(1):47-59. PubMed ID: 38532785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
